var data={"title":"Venetoclax: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Venetoclax: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/795893?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=venetoclax-patient-drug-information\" class=\"drug drug_patient\">see &quot;Venetoclax: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46443604\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Venclexta;</li>\n      <li>Venclexta Starting Pack</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49166304\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Venclexta</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46387202\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent;</li>\n      <li>\n        Antineoplastic Agent, BCL-2 Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46439803\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Assess risk for tumor lysis syndrome (TLS); administer prophylactic hydration and antihyperuricemics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic lymphocytic leukemia, relapsed/refractory, 17p deletion:</b> Oral: Escalate dose in weekly increments over 5 weeks to gradually debulk and reduce the risk of TLS:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Week 1: 20 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Week 2: 50 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Week 3: 100 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Week 4: 200 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Week 5 and thereafter: 400 mg once daily; continue until disease progression or unacceptable toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Premedications:</i> Hydration and antihyperuricemic therapy based on TLS risk:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Low tumor burden (all lymph nodes &lt;5 cm and absolute lymphocyte count [ALC] &lt;25,000/mm<sup>3</sup>): Outpatient: Hydrate with 1.5 to 2 L of oral hydration and administer allopurinol (beginning 2 to 3 days prior to venetoclax initiation). Administer IV hydration for patients unable to tolerate oral hydration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Medium tumor burden (any lymph node 5 to &lt;10 cm or ALC &ge;25,000/mm<sup>3</sup>): Outpatient: Hydrate with 1.5 to 2 L of oral hydration (administer IV hydration for patients unable to tolerate oral hydration; consider additional IV hydration) and administer allopurinol (beginning 2 to 3 days prior to venetoclax initiation).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">High tumor burden (any lymph node &ge;10 cm OR ALC &ge;25,000/mm<sup>3</sup> and any lymph node &ge;5 cm): Inpatient: Hydrate with 1.5 to 2 L of oral hydration (administer IV hydration for patients unable to tolerate oral hydration) and 150 to 200 mL/hour IV hydration as tolerated; administer allopurinol (beginning 2 to 3 days prior to venetoclax initiation); consider rasburicase if baseline uric acid is elevated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment for concomitant CYP3A and P-glycoprotein (P-gp) inhibitors:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Strong CYP3A inhibitors:</i> The use of strong CYP3A inhibitors is contraindicated at initiation of venetoclax and during dose escalation. For patients who have completed dose escalation and are on a steady daily venetoclax dose, reduce the venetoclax dose by at least 75% when a strong CYP3A inhibitor must be used concurrently.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Moderate CYP3A inhibitors and P-gp inhibitors:</i> Avoid concomitant use of venetoclax with moderate CYP3A and P-gp inhibitors (consider alternative treatments); if concurrent use cannot be avoided, reduce the venetoclax dose by at least 50%.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Following discontinuation of the CYP3A or P-gp inhibitor: 2 to 3 days after the inhibitor is discontinued, resume the venetoclax dose that was used prior to initiating the CYP3A or P-gp inhibitor.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46439826\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46439827\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary; use with caution due to increased risk for TLS. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">End-stage renal disease (ESRD) requiring dialysis: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Dialysis is unlikely to significantly remove venetoclax (due to large volume of distribution and extensive protein binding).  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46439828\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild impairment (normal total bilirubin and AST &gt; upper limit of normal [ULN] or total bilirubin &gt;1 to 1.5 times ULN): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate impairment (total bilirubin &gt;1.5 to 3 times ULN): No dosage adjustment necessary; monitor closely for signs of toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (total bilirubin &gt;3 times ULN): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46439829\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;display:inline\">Interrupt or reduce dose for toxicities. Reassess risk for tumor lysis syndrome in patients who have had an interruption in dosing of &gt;1 week during the first 5 weeks or &gt;2 weeks at 400 mg once daily (to determine if re-initiation with a reduced dose is necessary).</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Dose Reduction Levels for Venetoclax Toxicity</caption>\n      <col align=\"center\" class=\"header-col\"></col>\n      <col align=\"center\" class=\"header-col\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;text-align:center;\">Dose at interruption</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Restart dose<sup>a</sup></p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"2\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">Consider discontinuation for patients who require dose reductions to less than 100 mg for more than 2 weeks.</p></td></tr>\n        <tr>\n          <td colspan=\"2\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>a</sup>During dose escalation phase, continue the reduced dose for 1 week prior to increasing the dose.</p></td></tr></tfoot>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">400 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">300 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">300 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">200 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">200 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20 mg</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 mg</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Tumor lysis syndrome (TLS):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Blood chemistry changes or symptoms suggestive of TLS: Withhold the next day's dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If resolved within 24 to 48 hours of the last dose: Resume at the same dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If blood chemistry changes require more than 48 hours to resolve: Resume at a reduced dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clinical TLS (laboratory TLS with clinical consequences such as acute renal failure, cardiac arrhythmias, sudden death, and/or seizure): Withhold dose; following resolution, resume at a reduced dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic toxicity:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3 or 4 neutropenia with infection or fever or grade 4 hematologic toxicities (except lymphopenia):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">First occurrence: Interrupt treatment. May administer granulocyte-colony stimulating factors (G-CSFs) with venetoclax to reduce infection risk associated with neutropenia. May resume at the same dose once toxicity is resolved to grade 1 or baseline.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Second and subsequent occurrences: Interrupt treatment. Consider G-CSFs as clinically indicated. Resume at a lower dose level once toxicity is resolved (see dosage reduction levels in above table; a larger dose reduction may be necessary based on clinical discretion).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonhematologic toxicities, Grade 3 or 4 toxicity:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">First occurrence: Interrupt treatment. May resume at the same dose once toxicity is resolved to grade 1 or baseline (no dosage adjustment is necessary).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Second and subsequent occurrences: Interrupt treatment. Resume at a lower dose level once toxicity is resolved (see dosage reduction levels in above table; a larger dose reduction may be necessary based on clinical discretion).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46443605\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Venclexta: 10 mg, 50 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Therapy Pack, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Venclexta Starting Pack: Week 1: 10 mg (14); Week 2: 50 mg (7); Week 3: 100 mg (7); Week 4: 100 mg (14) (42 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46443603\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46439787\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Available through specialty pharmacies and distributors. Further information may be obtained from the manufacturer. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46502907\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Venclexta: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208573s003lbl.pdf#page=23&amp;token=qKqC/xg7KeMSLuHGplblFNB+wytSAxwUJZIbbZgi8cJH84NbLxLHVXT0V01OZ9ZcPV+0WMiWBT7LS2kBrI+ih9WyLerZOd/xRJkzedyV7MgqmMpItRaoPi02tQTFwmbO&amp;TOPIC_ID=107696\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208573s003lbl.pdf#page=23</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46439845\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer with a meal and water at approximately the same time each day. Swallow whole; do not crush, chew, or break.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Missed or vomited doses:</i> If a dose is missed and it is within 8 hours of the missed usual dosing time, administer the missed dose as soon as possible and resume the normal daily dosing schedule. If it is more than 8 hours, do not administer the missed dose and resume the usual dosing schedule the next day. If the patient vomits following administration of a dose, no additional doses should be administered that day; the next prescribed dose should be taken at the usual time.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49161144\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (meets NIOSH 2016 criteria). This medication is not on the NIOSH (2016) list; however, it meets the criteria for a hazardous drug. Drugs are classified as hazardous based on their properties; the properties of a hazardous drug include one or more of the following characteristics: carcinogenic, teratogenic (or other developmental toxicity), reproductive toxicity, organotoxic at low doses, genotoxic, and/or new agents with structural or toxicity profiles similar to existing hazardous agents. Assess risk to determine appropriate containment strategy (USP-NF 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46387204\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Chronic lymphocytic leukemia:</b> Treatment of chronic lymphocytic leukemia (CLL) in patients with 17p deletion (as detected by an approved test) who have received at least one prior therapy. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46439785\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Venetoclax may be confused with vandetanib, vemurafenib, venlafaxine, vismodegib</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Venclexta may be confused with venlafaxine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46443999\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (11%; grades 3/4: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (21%; grades 3/4: 2%), headache (15%; grades 3/4: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperkalemia (20%; &ge; grade 3: 2%), hyperphosphatemia (15%; &ge; grade 3: 3%), hypokalemia (12%; grades 3/4: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (35%; grades 3/4: &lt;1%), nausea (33%; grades 3/4: &lt;1%), vomiting (15%; grades 3/4: &lt;1%), constipation (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Neutropenia (45%; grades 3/4: 41%), anemia (29%; grades 3/4: 18%), thrombocytopenia (22%; grades 3/4: 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (22%; grades 3/4: 1%), cough (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (16%; grades 3/4: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypocalcemia (9%; &ge; grade 3: 3%), hyperuricemia (6%; &ge; grade 3: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Tumor lysis syndrome (2 to 3 week ramp-up phase: 12%; 5 week ramp-up phase: 6%; &ge; grade 3: 6%), febrile neutropenia (5%; grades 3/4: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (10%; grades 3/4: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pneumonia (8%; grades 3/4: 5%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46387205\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Concomitant use with strong CYP3A inhibitors at initiation and during ramp-up phase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Hypersensitivity to venetoclax or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46439791\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Neutropenia, thrombocytopenia, and anemia may occur. Grade 3 and 4 neutropenia occurred in almost half of patients receiving venetoclax. Neutropenic fever has been reported. Monitor CBC with differential throughout treatment. May require treatment interruption and/or dose reduction. Consider antimicrobials and WBC growth factor support as clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: Venetoclax may cause a rapid reduction in tumor volume and therefore a risk for tumor lysis syndrome (TLS) is present during the initial 5-week dose escalation phase of treatment. TLS has occurred with venetoclax in previously treated chronic lymphocytic leukemia (CLL) patients with high tumor burden; renal failure (requiring dialysis) and fatalities have been reported. Changes in blood chemistries consistent with TLS may occur as early as 6 to 8 hours after the first dose and with dose increases, and require prompt management. The risk for TLS is increased with high tumor burden and comorbidities; creatinine clearance &lt;80 mL/minute further increases TLS risk. Assess risk for TLS; initiate appropriate TLS prophylactic management (eg, hydration and antihyperuricemic therapy); monitor blood chemistries closely and manage abnormalities promptly. May require treatment interruption and dose reduction. The risk for TLS may decrease as tumor burden decreases. Patients at high risk for TLS may require hospitalization at treatment initiation. Concomitant use of CYP3A or P-gp inhibitors at initiation or during dose escalation may increase the risk for TLS.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Adverse events may be increased in patients with moderate impairment; monitor closely for toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Patients with decreased renal function (CrCl &lt;80 mL/minute) are at increased risk for TLS and may require more intensive TLS prophylaxis and monitoring during treatment initiation and dose escalation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Select patients for treatment (of relapsed or refractory chronic lymphocytic leukemia) based on the presence of a 17p deletion. Patients without a 17p deletion at diagnosis should be re-tested at relapse as acquisition of 17p deletion may occur.  Information on approved tests for 17p deletion detection may be found at <a target=\"_blank\" href=\"http://www.fda.gov/CompanionDiagnostics&amp;token=SHauxSdf9qNc6lLK16E8IPc+kYYsON95PtA1EteUbfjUoJYJ+uveJw2PtFUTXMkK&amp;TOPIC_ID=107696\" target=\"_blank\">http://www.fda.gov/CompanionDiagnostics</a>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Live vaccinations should not be administered prior to, during, or after venetoclax treatment until B-cell recovery occurs. Vaccines may be less effective.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46440279\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46440276\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=107696&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bitter Orange: May increase the serum concentration of Venetoclax.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Venetoclax.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Venetoclax.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Venetoclax. Management: Reduce the venetoclax dose by at least 50% in patients requiring these combinations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Venetoclax. Management: These combinations are contraindicated during venetoclax initiation and ramp-up. In patients receiving steady venetoclax doses after completing ramp-up, reduce the venetoclax by at least 75% if strong CYP3A4 inhibitor use cannot be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: Venetoclax may increase the serum concentration of Digoxin.  Management: Administer digoxin at least 6 hours before venetoclax when concomitant therapy is required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Everolimus: Venetoclax may increase the serum concentration of Everolimus.  Management: Administer everolimus at least 6 hours before venetoclax when concomitant therapy is required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of Venetoclax.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Venetoclax. Management: Reduce the venetoclax dose by at least 50% in patients requiring these combinations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sirolimus: Venetoclax may increase the serum concentration of Sirolimus.  Management: Administer sirolimus at least 6 hours before venetoclax when concomitant therapy is required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Star Fruit: May increase the serum concentration of Venetoclax.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Venetoclax may diminish the therapeutic effect of Vaccines (Inactivated). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Venetoclax may enhance the adverse/toxic effect of Vaccines (Live). Venetoclax may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live, attenuated vaccines before, during, or after (prior to B-cell recovery) venetoclax treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Warfarin: Venetoclax may increase the serum concentration of Warfarin. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49002455\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Coadministration with grapefruit products, Seville oranges, and/or Star Fruit may increase venetoclax plasma concentrations. Management: Avoid concomitant administration with grapefruit products, Seville oranges, and Star Fruit.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46439789\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Based on the mechanism of action and data from animal reproduction studies, venetoclax is expected to cause fetal harm if administered during pregnancy. Females of reproductive potential should have a pregnancy test prior to therapy, and use effective contraception during treatment and for at least 30 days after the final dose. Based on animal data, venetoclax may compromise fertility in males. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46439790\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if venetoclax is excreted in breast milk. Due to the potential for serious adverse reactions in the breast-feeding infant, breast-feeding is not recommended by the manufacturer. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46439844\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;\">Administration with a low-fat meal increased exposure by ~3.4 fold and administration with a high-fat meal increased exposure by ~5.1 to 5.3 fold, compared to fasting. Avoid grapefruit products, Seville oranges, and Star Fruit.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46439847\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">17p deletion status (prior to treatment initiation or at relapse); pregnancy test (prior to treatment in females of reproductive potential); CBC with differential (throughout treatment); blood chemistries (potassium, uric acid, phosphorus, calcium, and creatinine); assess tumor burden, including radiographic evaluation (eg, CT scan) for tumor lysis syndrome (TLS) risk evaluation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood chemistry monitoring based on tumor burden/TLS risk: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Low risk (all lymph node &lt;5 cm and absolute lymphocyte count [ALC] &lt;25,000/mm<sup>3</sup>) or medium risk (any lymph node 5 to &lt;10 cm or ALC &ge;25,000/mm<sup>3</sup>): Prior to first dose, 6 to 8 hours, and 24 hours after first 20 mg and 50 mg dose, and prior to each subsequent initial ramp up dose. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">High risk (any lymph node &ge;10 cm OR ALC &ge;25,000/mm<sup>3</sup> and any lymph node &ge;5 cm): Prior to first dose, 4, 8, 12, and 24 hours after first 20 mg and 50 mg dose, and prior to plus 6 to 8 hours and 24 hours after each subsequent initial ramp up dose.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46439794\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Venetoclax has cytotoxic activity in tumor cells which overexpress BCL-2. Venetoclax selectively inhibits the anti-apoptotic protein BCL-2, which is overexpressed in chronic lymphocytic leukemia (CLL) cells. BCL-2 mediates tumor cell survival and has been associated with chemotherapy resistance. Venetoclax binds directly to the BCL-2 protein, displacing pro-apoptotic proteins and restoring the apoptotic process. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46439796\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: 256 to 321 L </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Highly bound to plasma proteins</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic, predominantly via CYP3A4/5; the major metabolite is M27 (has BCL-2 inhibitory activity) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life, elimination: ~26 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 5 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (&gt;99.9%; ~21% as unchanged drug); Urine (&lt;0.1%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46817117\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Therapy Pack</b> (Venclexta Starting Pack Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 &amp; 50 &amp; 100 mg (42): $2,887.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Venclexta Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (2): $22.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $55.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $111.49</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49940153\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Venclexta (AR, AU, IL, SA);</li>\n      <li>Venclyxto (AT, CZ, DE, DK, EE, FR, GB, HR, HU, LT, LU, LV, NL, NO, PT, RO, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016;374(4):311-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/26639348/pubmed\" target=\"_blank\" id=\"26639348\">26639348</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. <i>Lancet Oncol</i>. 2016;17(6):768-778.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/venetoclax-drug-information/abstract-text/27178240/pubmed\" target=\"_blank\" id=\"27178240\">27178240</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 3, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Venclexta (venetoclax) [prescribing information]. North Chicago, IL: AbbVie Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Venclexta (venetoclax) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; September 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 107696 Version 44.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F46443604\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F49166304\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F46387202\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F46439803\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F46439826\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F46439827\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F46439828\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F46439829\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F46443605\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F46443603\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F46439787\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F46502907\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F46439845\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49161144\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F46387204\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F46439785\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F46443999\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F46387205\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F46439791\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F46440279\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F46440276\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F49002455\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F46439789\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F46439790\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F46439844\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F46439847\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F46439794\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F46439796\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F46817117\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F49940153\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/107696|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=venetoclax-patient-drug-information\" class=\"drug drug_patient\">Venetoclax: Patient drug information</a></li></ul></div></div>","javascript":null}